Press Releases

Fluorine-18 Market to Expand at a CAGR of 7.4 % from 2021 to 2030

Share This Article

The global Fluorine-18 market size is expected to reach USD 1.4 billion by 2030 and is expected to expand at a CAGR of 7.4% from 2021 to 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38533

Fluorine-18 is the most important radionuclide used in positron emission tomography (PET) today, largely due to its unique physical and nuclear characteristics. Agents such as the clinical oncology tracer FDG, the most widely used PET-radiopharmaceutical, have driven interest toward the chemistry of radiopharmaceuticals utilizing fluorine-18.

Positron emission tomography, also called PET imaging or a PET scan, is a type of nuclear medicine imaging, which is primarily carried out through radioactive material. Nuclear medicine imaging uses small amounts of radioactive material to diagnose, evaluate, or treat diseases, and fluorine-18 is widely used in PET scan.

Fluorine-18 is the most widely used radioisotope in positron emission tomography (PET). It has a number of applications in the fields of oncology, neurology, and cardiology.

Combined PET/CT scanners outperform nearly all PET scans today. These combined scans help pinpoint abnormal metabolic activity and could provide more accurate diagnoses than the two scans performed separately. This is a major factor projected to drive the demand for fluorine-18.

Clinical applications of the positron emission tomography/computed tomography (PET-CT) with glucose analogue 2-[fluorine 18] fluoro-2-deoxy-D-glucose (FDG) are expanding beyond the area of oncology. Apart from its high usage in clinical oncology, FDG PET-CT is used in various non-oncologic specialties such as cardiology, neurology, and cognitive neuroscience. This boosts the growth the global fluorine-18 market.

Increase in incidence of cancer across the globe boosts the demand for PET-CT devices. PET-CT test helps to diagnose cancer and provides more information, including whether a tumor is benign or malignant, and how well the cancer is responding to treatment. PET-CT is an extremely sensitive imaging modality in the detection of malignant tissues and presents higher specificity than PET alone, which is the primary reason for fewer equivocal scans and better diagnostic results.

FDG to Dominate Global Market

The global fluorine-18 market has been segmented based on product and end user. In terms of product, the global fluorine-18 market has been classified into FDG, NaF, and others. The FDG segment is expected to account for a major share of the global market by 2030, due to the increase in demand for PET/CT scan in oncology.

Hospitals to be Major End User

In terms of end user, the global fluorine-18 market has been divided into hospitals, diagnostic centers, and others. The hospitals segment is likely to expand at a high CAGR during the forecast period, due to the increase in the demand for the installation of new PET-CT machines in the upcoming hospital projects across the globe, which drive the demand for F-18 isotopes.

North America to Dominate Global Market

The global fluorine-18 market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global fluorine-18 market in 2020, followed by Europe. The fluorine-18 market in Asia Pacific is projected to expand at a high CAGR from 2021 to 2030. Product launches, acquisitions, distribution agreements, alliances, and geographical expansion by local players, especially in China and India, are anticipated to drive the fluorine-18 market in the region.

Key Players

The report also presents profiles of leading players in the global fluorine-18 market. These include Lantheus Holdings, Inc., Siemens Healthineers, Advanced Accelerator Applications (a Novartis AG Company), GE Healthcare (General Electric Company), Blue Earth Diagnostics (A Bracco Imaging Company), Jubilant Pharma Limited, China lsotope & Radiation Corporation, Eli Lilly and Company, Curium Pharma, and Yantai Dongcheng Pharmaceutical Group Co., Ltd.

Global Fluorine-18 Market: Segmentation

Fluorine-18 Market, by Product

    • FDG
    • NaF
    • Others

Fluorine-18 Market, by End User

    • Hospitals
    • Diagnostic Centers
    • Others

Fluorine-18 Market, by Region

    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • GCC Countries
      • South Africa
      • Rest of Middle East & Africa

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38533

Research Methodology

The research methodology adopted by analysts for compiling the global fluorine-18 market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global fluorine-18 market.

Table of Contents

Chapter 1.    Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.    Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.    Executive Summary

3.1.  Market Snapshot

Chapter 4.    Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.     Raw Material Procurement Analysis

4.3.2.     Sales and Distribution Channel Analysis

4.3.3.     Downstream Buyer Analysis

Chapter 5.    Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.     Market Drivers

5.1.2.     Market Restraints

5.1.3.     Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.     Bargaining power of suppliers

5.2.2.     Bargaining power of buyers

5.2.3.     Threat of substitute

5.2.4.     Threat of new entrants

5.2.5.     Degree of competition

Chapter 6.    Competitive Landscape

6.1.1.     Company Market Share/Positioning Analysis

6.1.2.     Key Strategies Adopted by Players

6.1.3.     Vendor Landscape

6.1.3.1.          List of Suppliers

6.1.3.2.          List of Buyers

Chapter 7.    Global Fluorine-18 Market, By Product

7.1.  Fluorine-18 Market, by Product, 2021-2030

7.1.1.     FDG

7.1.1.1.          Market Revenue and Forecast (2016-2030)

7.1.2.     NaF

7.1.2.1.          Market Revenue and Forecast (2016-2030)

7.1.3.     Others

7.1.3.1.          Market Revenue and Forecast (2016-2030)

Chapter 8.    Global Fluorine-18 Market, By End User

8.1.  Fluorine-18 Market, by End User, 2021-2030

8.1.1.     Hospitals

8.1.1.1.          Market Revenue and Forecast (2016-2030)

8.1.2.     Diagnostic Centers

8.1.2.1.          Market Revenue and Forecast (2016-2030)

8.1.3.     Others

8.1.3.1.          Market Revenue and Forecast (2016-2030)

Chapter 9.    Global Fluorine-18 Market, Regional Estimates and Trend Forecast

9.1.  North America

9.1.1.     Market Revenue and Forecast, by Product (2016-2030)

9.1.2.     Market Revenue and Forecast, by End User (2016-2030)

9.1.3.     U.S.

9.1.3.1.          Market Revenue and Forecast, by Product (2016-2030)

9.1.3.2.          Market Revenue and Forecast, by End User (2016-2030)

9.1.4.     Rest of North America

9.1.4.1.          Market Revenue and Forecast, by Product (2016-2030)

9.1.4.2.          Market Revenue and Forecast, by End User (2016-2030)

9.2.  Europe

9.2.1.     Market Revenue and Forecast, by Product (2016-2030)

9.2.2.     Market Revenue and Forecast, by End User (2016-2030)

9.2.3.     UK

9.2.3.1.          Market Revenue and Forecast, by Product (2016-2030)

9.2.3.2.          Market Revenue and Forecast, by End User (2016-2030)

9.2.4.     Germany

9.2.4.1.          Market Revenue and Forecast, by Product (2016-2030)

9.2.4.2.          Market Revenue and Forecast, by End User (2016-2030)

9.2.5.     France

9.2.5.1.          Market Revenue and Forecast, by Product (2016-2030)

9.2.5.2.          Market Revenue and Forecast, by End User (2016-2030)

9.2.6.     Rest of Europe

9.2.6.1.          Market Revenue and Forecast, by Product (2016-2030)

9.2.6.2.          Market Revenue and Forecast, by End User (2016-2030)

9.3.  APAC

9.3.1.     Market Revenue and Forecast, by Product (2016-2030)

9.3.2.     Market Revenue and Forecast, by End User (2016-2030)

9.3.3.     India

9.3.3.1.          Market Revenue and Forecast, by Product (2016-2030)

9.3.3.2.          Market Revenue and Forecast, by End User (2016-2030)

9.3.4.     China

9.3.4.1.          Market Revenue and Forecast, by Product (2016-2030)

9.3.4.2.          Market Revenue and Forecast, by End User (2016-2030)

9.3.5.     Japan

9.3.5.1.          Market Revenue and Forecast, by Product (2016-2030)

9.3.5.2.          Market Revenue and Forecast, by End User (2016-2030)

9.3.6.     Rest of APAC

9.3.6.1.          Market Revenue and Forecast, by Product (2016-2030)

9.3.6.2.          Market Revenue and Forecast, by End User (2016-2030)

9.4.  MEA

9.4.1.     Market Revenue and Forecast, by Product (2016-2030)

9.4.2.     Market Revenue and Forecast, by End User (2016-2030)

9.4.3.     GCC

9.4.3.1.          Market Revenue and Forecast, by Product (2016-2030)

9.4.3.2.          Market Revenue and Forecast, by End User (2016-2030)

9.4.4.     North Africa

9.4.4.1.          Market Revenue and Forecast, by Product (2016-2030)

9.4.4.2.          Market Revenue and Forecast, by End User (2016-2030)

9.4.5.     South Africa

9.4.5.1.          Market Revenue and Forecast, by Product (2016-2030)

9.4.5.2.          Market Revenue and Forecast, by End User (2016-2030)

9.4.6.     Rest of MEA

9.4.6.1.          Market Revenue and Forecast, by Product (2016-2030)

9.4.6.2.          Market Revenue and Forecast, by End User (2016-2030)

9.5.  Latin America

9.5.1.     Market Revenue and Forecast, by Product (2016-2030)

9.5.2.     Market Revenue and Forecast, by End User (2016-2030)

9.5.3.     Brazil

9.5.3.1.          Market Revenue and Forecast, by Product (2016-2030)

9.5.3.2.          Market Revenue and Forecast, by End User (2016-2030)

9.5.4.     Rest of LATAM

9.5.4.1.          Market Revenue and Forecast, by Product (2016-2030)

9.5.4.2.          Market Revenue and Forecast, by End User (2016-2030)

Chapter 10.   Company Profiles

10.1.                 Lantheus Holdings, Inc.

10.1.1.  Company Overview

10.1.2.  Product Offerings

10.1.3.  Financial Performance

10.1.4.  Recent Initiatives

10.2.                 Siemens Healthineers

10.2.1.  Company Overview

10.2.2.  Product Offerings

10.2.3.  Financial Performance

10.2.4.  Recent Initiatives

10.3.                 Advanced Accelerator Applications (a Novartis AG Company)

10.3.1.  Company Overview

10.3.2.  Product Offerings

10.3.3.  Financial Performance

10.3.4.  Recent Initiatives

10.4.                 GE Healthcare (General Electric Company)

10.4.1.  Company Overview

10.4.2.  Product Offerings

10.4.3.  Financial Performance

10.4.4.  Recent Initiatives

10.5.                 Blue Earth Diagnostics (A Bracco Imaging Company)

10.5.1.  Company Overview

10.5.2.  Product Offerings

10.5.3.  Financial Performance

10.5.4.  Recent Initiatives

10.6.                 Jubilant Pharma Limited

10.6.1.  Company Overview

10.6.2.  Product Offerings

10.6.3.  Financial Performance

10.6.4.  Recent Initiatives

10.7.                 China lsotope & Radiation Corporation

10.7.1.  Company Overview

10.7.2.  Product Offerings

10.7.3.  Financial Performance

10.7.4.  Recent Initiatives

10.8.                 Eli Lilly and Company

10.8.1.  Company Overview

10.8.2.  Product Offerings

10.8.3.  Financial Performance

10.8.4.  Recent Initiatives

10.9.                 Curium Pharma

10.9.1.  Company Overview

10.9.2.  Product Offerings

10.9.3.  Financial Performance

10.9.4.  Recent Initiatives

10.10.              Yantai Dongcheng Pharmaceutical Group Co., Ltd.

10.10.1.                   Company Overview

10.10.2.                   Product Offerings

10.10.3.                   Financial Performance

10.10.4.                   Recent Initiatives

Chapter 11.   Research Methodology

11.1.                 Primary Research

11.2.                 Secondary Research

11.3.                 Assumptions

Chapter 12.   Appendix

12.1.                 About Us

12.2.                 Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38533

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com

Related Articles

Back to top button